Charles River Laboratories | CRL - Ebit

Stock Price
172.65
Daily Change
2.85 1.68%
Monthly
8.10%
Yearly
50.03%
Q2 Forecast
166.17

Charles River Laboratories reported $75.82M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Agilent USD 353M 90M Dec/2025
Align Technology USD 224.71M 40.06M Dec/2025
Bio-Rad Laboratories USD -418.8M 845.4M Sep/2025
Bruker USD 76.3M 7.6M Dec/2025
Cardinal Health USD 763M 9M Dec/2025
Charles River Laboratories USD 75.82M 57.98M Dec/2025
Cigna USD 2.58B 220M Sep/2025
Concord Medical Services Hldg CNY -144.65M 69.38M Jun/2025
CVS Health USD 2.11B 836M Dec/2025
Danaher USD 1.34B 158M Mar/2026
Dentsply International USD 538M 26M Dec/2025
Elevance Health USD -5.81B 6.39B Mar/2026
Galapagos EUR 780.56M 822.23M Dec/2025
Humana USD -808M 1.21B Dec/2025
Illumina USD 256M 6M Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Intrexon USD -26.3M 2.91M Jun/2024
IQVIA Holdings USD 2.68B 2.1B Dec/2025
Laboratory Of America USD 382M 11M Dec/2025
Lonza CHF 673M 54M Jun/2025
McKesson USD 1.66B 159M Dec/2025
Merck EUR 474M 738M Dec/2025
Mettler Toledo International USD 351.93M 57.73M Dec/2025
Novartis USD 4.06B 530M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Quest Diagnostics USD 399M 13M Mar/2026
Revvity USD 145.83M 47.49M Dec/2025
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
United Therapeutics USD -14.6M 403.9M Dec/2025
UnitedHealth USD 9.04B 5.78B Mar/2026
Veradigm USD -45.47M 70.47M Dec/2022
Waters USD 270.52M 78.4M Dec/2025
West Pharmaceutical Services USD 177.1M 14.6M Mar/2026